Hikma Pharmaceuticals Plc 20.3% potential upside indicated by Barclays

Hikma Pharmaceuticals Plc with ticker (LON:HIK) now has a potential upside of 20.3% according to Barclays.



Barclays set a target price of 3,000 GBX for the company, which when compared to the Hikma Pharmaceuticals Plc share price of 2,390 GBX at opening today (08/11/2021) indicates a potential upside of 20.3%. Trading has ranged between 2,158 (52 week low) and 2,714 (52 week high) with an average of 370,581 shares exchanging hands daily. The market capitalisation at the time of writing is £5,552,612,164.

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 300 products in different dosage strengths and forms. The Company’s other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.